Sign inGet started

Bausch Christoph Lawrence

Insider CIK 1889981 · SABS Chief Science Officer

Track record PRO

XXXX$█.██M██+██%
XXXX$█.██M██+██%
XXXX$█.██M██+██%
Track record
See how this insider's past purchases performed 30 and 90 days later, and a conviction score on each buy.
Upgrade to Pro · $99/yearAlready Pro? Log in

Trades across companies

TickerCodeTradeFiledSharesPriceValueOwned after
SABS SAB Biotherapeutics, Inc. A Award deriv2026-02-032026-02-051,800,000— $01,800,000SEC↗
SABS SAB Biotherapeutics, Inc. A Award deriv2025-08-262025-08-28600,000— $0600,000SEC↗
SABS SAB Biotherapeutics, Inc. A Award deriv2024-02-212024-02-23140,000— $0140,000SEC↗
SABS SAB Biotherapeutics, Inc. A Award deriv2023-03-142023-03-16275,000— $0275,000SEC↗
SABS SAB Biotherapeutics, Inc. A Award deriv2022-09-132022-09-15274,875— $0274,875SEC↗
SABS SAB Biotherapeutics, Inc. A Award deriv2022-03-162022-03-1824,972— $024,972SEC↗
SABS SAB Biotherapeutics, Inc. A Award deriv2021-10-222021-10-26108,086— $0108,086SEC↗
SABS SAB Biotherapeutics, Inc. A Award deriv2021-10-222021-10-2611,632— $011,632SEC↗
SABS SAB Biotherapeutics, Inc. A Award deriv2021-10-222021-10-2669,793— $069,793SEC↗
SABS SAB Biotherapeutics, Inc. A Award deriv2021-10-222021-10-2681,425— $081,425SEC↗
SABS SAB Biotherapeutics, Inc. A Award deriv2021-10-222021-10-26104,689— $0104,689SEC↗
SABS SAB Biotherapeutics, Inc. A Award deriv2021-10-222021-11-24104,689— $0104,689SEC↗
SABS SAB Biotherapeutics, Inc. A Award deriv2021-10-222021-11-2481,425— $081,425SEC↗
SABS SAB Biotherapeutics, Inc. A Award deriv2021-10-222021-11-24108,086— $0108,086SEC↗